Vimian Group AB (publ)
Vimian Group AB (publ)
Your view on VIMGF
Overview
What the company does, where it operates, and who runs it.
About Vimian Group AB (publ)
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Alireza Tajbakhsh
- Headquarters
- Riddargatan 19, Stockholm, SE
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Alireza Tajbakhsh
- Headquarters
- Riddargatan 19, Stockholm, SE
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments.
The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name.
The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Vimian Group AB (publ), and the rating behind it. VIMGF last traded at $2.77, 43.6× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Vimian Group AB (publ). Starting points for Vimian Group AB (publ): P/E 43.6, EPS $0.07, beta 1.42 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Vimian Group AB (publ). Vimian Group AB (publ) does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Vimian Group AB (publ). Trailing twelve-month EPS for Vimian Group AB (publ) stands at $0.07. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Vimian Group AB (publ). Vimian Group AB (publ) has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Vimian Group AB (publ) valued side by side against its closest peers. Vimian Group AB (publ) is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Vimian Group AB (publ), and how their positions are changing. At a $1.46B market value, institutional positions materially move Vimian Group AB (publ)'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Vimian Group AB (publ) executives and directors. Shares of Vimian Group AB (publ) have traded between $2.68 and $4.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Vimian Group AB (publ). Vimian Group AB (publ) is a $1.46B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Vimian Group AB (publ). Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Vimian Group AB (publ). Coverage tracks Vimian Group AB (publ) within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.